Vaccination is increasingly acknowledged as an effective preventive measure not only against specific infections, but also for the prevention of cardiovascular disease in high-risk patients. Specifically, a growing body of evidence suggests that vaccines against influenza, SARS-CoV-2, respiratory syncytial virus, herpes zoster, and other viruses significantly reduce infection and for influenza the incidence of major adverse cardiovascular events in vaccinated individuals. This clinical consensus statement examines the existing literature and accumulated evidence and offers practical clinical advice on vaccination timing and target demographics, specifically addressing complex clinical scenarios with a focus on cardiovascular conditions. It includes guidelines for vaccinating vulnerable populations such as immunosuppressed individuals, patients with congenital heart disease, and pregnant women as well as safety and potential complications of the procedure.

Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement / Heidecker, B.; Libby, P.; Vassiliou, V. S.; Roubille, F.; Vardeny, O.; Hassager, C.; Gatzoulis, M. A.; Mamas, M. A.; Cooper, L. T.; Schoenrath, F.; Metra, M.; Amir, O.; Solomon, S. D.; Landmesser, U.; Luscher, T. F.. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - 46:36(2025), pp. 3518-3531. [10.1093/eurheartj/ehaf384]

Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement

Metra M.;
2025-01-01

Abstract

Vaccination is increasingly acknowledged as an effective preventive measure not only against specific infections, but also for the prevention of cardiovascular disease in high-risk patients. Specifically, a growing body of evidence suggests that vaccines against influenza, SARS-CoV-2, respiratory syncytial virus, herpes zoster, and other viruses significantly reduce infection and for influenza the incidence of major adverse cardiovascular events in vaccinated individuals. This clinical consensus statement examines the existing literature and accumulated evidence and offers practical clinical advice on vaccination timing and target demographics, specifically addressing complex clinical scenarios with a focus on cardiovascular conditions. It includes guidelines for vaccinating vulnerable populations such as immunosuppressed individuals, patients with congenital heart disease, and pregnant women as well as safety and potential complications of the procedure.
2025
COVID-19
Infection
Influenza
Pneumococcus
Respiratory syncytial virus
File in questo prodotto:
File Dimensione Formato  
ehaf384.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Tutti i diritti riservati
Dimensione 1.32 MB
Formato Adobe PDF
1.32 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/200276
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 39
social impact